Skip to main content

Site notifications

Boostrix-IPV GlaxoSmithKline Australia Pty Ltd

Product name
Boostrix-IPV
Accepted date
Oct-2024
Active ingredients
Diphtheria toxoid, Pertactin, Pertussis filamentous haemagglutinin, Pertussis toxoid, Poliovirus, Tetanus toxoid
Proposed indication
BOOSTRIX-IPV is a booster vaccine for people aged four and older (boosters are additional vaccinations given after the initial vaccination to enhance the immune response against the microbe). BOOSTRIX-IPV protects against diphtheria, tetanus, whooping cough (pertussis), and polio. It also helps protect newborns from whooping cough if their mothers get vaccinated during pregnancy.
Application type
C (new indication)
Publication date
Oct-2024

Help us improve the Therapeutic Goods Administration site